PPARD Activation Reprograms Immune Cells to Fight Cancer — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cold Spring Harbor Laboratory scientists published findings in Nature Immunology showing that activating the PPARD protein in immune cells can transform them into more effective cancer killers.
- Lead investigator Semir Beyaz demonstrated that while PPARD fuels cancer cell growth, activating the same protein in immune cells boosts their metabolism to attack tumors — drawing a parallel to how 'the force' in Star Wars can serve either side.
- PPARD-activated CAR T cells slowed or stopped tumor growth in organoids, lab-cultured cancer cells, and mouse models of human colorectal cancer.
- The approach also showed promise against breast cancer, ovarian cancer, and melanoma, suggesting broader applicability beyond the initial colorectal cancer focus.
- The research targets colorectal cancer, now the leading cause of cancer-related death among people under 50, where many patients have limited options when chemotherapy and existing immunotherapies fail.
- Beyaz's lab is now exploring whether PPARD activation could help treat endometriosis, a chronic inflammatory condition affecting roughly one in 10 women.
- The approach has not yet been tested in human patients, though researchers call the findings the 'tip of the iceberg' for strengthening cancer immunotherapy.
Why it matters: Colorectal cancer is now the leading cancer killer of adults under 50, and patients with treatment-resistant disease have few remaining options. By showing that PPARD activation can enhance CAR T cell performance against multiple tumor types, the research points toward a potential new immunotherapy strategy — though the approach remains confined to laboratory and animal models.
Ask SkimNews
